Clark Estates Inc. NY Has $2.97 Million Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

Key Points

• Clark Estates Inc. NY has decreased its stake in Pediatrix Medical Group, Inc. by 27.6%, owning now 204,613 shares valued at approximately $2.97 million.
• Pediatrix Medical Group recently reported an EPS of $0.33 for the last quarter, surpassing analysts' consensus estimates, despite a year-over-year revenue decline of 7.4%.
• The stock currently has a consensus rating of "Hold" and a target price of $16.67, with several brokerage firms adjusting their price targets on the stock.

Clark Estates Inc. NY decreased its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 27.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,613 shares of the company's stock after selling 78,127 shares during the period. Pediatrix Medical Group comprises approximately 0.6% of Clark Estates Inc. NY's investment portfolio, making the stock its 19th largest holding. Clark Estates Inc. NY owned approximately 0.24% of Pediatrix Medical Group worth $2,965,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Oberweis Asset Management Inc. purchased a new position in shares of Pediatrix Medical Group during the 4th quarter worth $6,122,000. Renaissance Technologies LLC increased its position in shares of Pediatrix Medical Group by 117.4% during the 4th quarter. Renaissance Technologies LLC now owns 838,800 shares of the company's stock worth $11,005,000 after purchasing an additional 453,000 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in shares of Pediatrix Medical Group during the 4th quarter worth about $3,882,000. Nuveen Asset Management LLC increased its position in shares of Pediatrix Medical Group by 110.8% during the 4th quarter. Nuveen Asset Management LLC now owns 485,587 shares of the company's stock worth $6,371,000 after purchasing an additional 255,273 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Pediatrix Medical Group during the 4th quarter worth about $3,066,000. Hedge funds and other institutional investors own 97.71% of the company's stock.

Wall Street Analysts Forecast Growth

MD has been the subject of several analyst reports. Macquarie upped their price target on Pediatrix Medical Group from $19.00 to $20.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Truist Financial decreased their price objective on Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Finally, UBS Group cut their price objective on shares of Pediatrix Medical Group from $18.50 to $16.00 and set a "neutral" rating on the stock in a report on Monday, May 12th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $16.67.

Pediatrix Medical Group Price Performance

Shares of MD traded down $0.28 during mid-day trading on Wednesday, reaching $12.39. The company had a trading volume of 529,121 shares, compared to its average volume of 544,498. Pediatrix Medical Group, Inc. has a twelve month low of $7.47 and a twelve month high of $17.67. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.81 and a quick ratio of 1.81. The company's 50-day moving average is $13.50 and its 200-day moving average is $13.85. The company has a market capitalization of $1.06 billion, a P/E ratio of -12.27 and a beta of 1.25.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.08. Pediatrix Medical Group had a positive return on equity of 17.43% and a negative net margin of 4.17%. The firm had revenue of $458.36 million during the quarter, compared to analysts' expectations of $451.44 million. During the same period last year, the firm posted $0.20 EPS. The business's revenue was down 7.4% on a year-over-year basis. On average, equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.